[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.173.48.53. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,289
Citations 0
Viewpoint
May 28, 2020

Neoadjuvant Treatment for Patients With Localized Pancreatic Adenocarcinoma: Are We There Yet?

Author Affiliations
  • 1Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Epidemiology, and Population Sciences, Baylor College of Medicine, Houston, Texas
  • 2Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston
  • 3Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas
  • 4Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
JAMA Oncol. Published online May 28, 2020. doi:10.1001/jamaoncol.2020.0562

Nearly every published study related to the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) opens with a description of the poor long-term survival associated with the diagnosis, and many further emphasize that resection is the only potentially curative treatment option. While both points are for the most part factual, neither really tells the whole story. With contemporary systemic therapy regimens, long-term survivors are increasingly identified.1 There is also an evolving understanding that while surgery is potentially curative, this is particularly the case when it is not used as a stand-alone intervention but rather incorporated as part of multimodality therapy (MMT) that includes chemotherapy, concurrent chemoradiotherapy, or both.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×